Blend Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Blend Labs, Inc. (NYSE: BLND) on April 28, 2023, with the report date reflecting the earliest event reported. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed is the market price of the Company's Class A Common Stock, which averaged less than $1.00 per share over a consecutive 30 trading-day period ending April 27, 2023.
Material Changes and Listing Status
On April 28, 2023, the Company received notice from the NYSE that it failed to meet the minimum bid price requirement under Section 802.01C of the Listed Company Manual. The deficiency is attributed to the average closing price of the Common Stock falling below $1.00 per share. The stock remains listed and traded on the NYSE during the cure period, and the notice has no immediate impact on business operations or SEC reporting obligations.
Outlook, Management Commentary, and Risks
The Company has a six-month cure period to regain compliance. Management plans to notify the NYSE within 10 business days of its intent to cure the deficiency. Potential actions include effecting a reverse stock split, subject to Board and stockholder approval. The Company is also undertaking business initiatives intended to increase stockholder value and drive share price increases. Compliance can be achieved if the closing share price reaches at least $1.00 and the 30-day average closing price reaches at least $1.00 by the last trading day of any calendar month during the cure period. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of these efforts.
Key Facts for Investor Verification
- Delisting Risk: The Company is currently non-compliant with NYSE minimum price standards and faces potential delisting if compliance is not achieved within six months.
- Remediation Plan: A reverse stock split is a potential cure method but requires Board and stockholder approval.
- Operational Impact: The notice does not affect current business operations or SEC reporting duties.
- Financial Data: This 8-K contains no revenue, earnings, or balance sheet data; investors must refer to the most recent 10-K or 10-Q for financial performance.